Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
Listed Suppliers
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Cp 89044
2. Cp 90033
3. Cp-89044
4. Cp-90033
5. Cp89044
6. Cp90033
7. Gonadotropin, Human Menopausal
8. Gonadotropins, Human Menopausal
9. Hmg Ferring
10. Hmg Lepori
11. Hmg Massone
12. Human Menopausal Gonadotropin
13. Human Menopausal Gonadotropins
14. Humegon
15. Lepori, Hmg
16. Menogon
17. Menopausal Gonadotropin, Human
18. Menopur
19. Menotrophin
20. Menotropins
21. Normegon
22. Org 31338
23. Org-31338
24. Org31338
25. Pergonal
26. Pergonal 500
27. Pergonal-500
28. Pergonal500
1. 6,6-dimethylheptanal
2. Menotrophin
3. 61489-71-2
4. Menotropins
5. Schembl1784550
6. Akos013847259
7. Gonadotropin From Human Menopausal Urine
| Molecular Weight | 142.24 g/mol |
|---|---|
| Molecular Formula | C9H18O |
| XLogP3 | 3 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 1 |
| Rotatable Bond Count | 5 |
| Exact Mass | 142.135765193 g/mol |
| Monoisotopic Mass | 142.135765193 g/mol |
| Topological Polar Surface Area | 17.1 Ų |
| Heavy Atom Count | 10 |
| Formal Charge | 0 |
| Complexity | 89.4 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
MENOTROPINS FOR INJECTION (PERGONAL)... WHILE FSH & LH ACTIVITIES ARE PRESENT IN EQUAL UNITAGE, CHORIONIC GONADOTROPIN IS USUALLY REQUIRED IN CONJUNCTION WITH MENOTROPINS TO INDUCE OVULATION.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1388
WIDEST POTENTIAL USEFULNESS OF GONADOTROPINS IS IN INDUCTION OF OVULATION IN WOMEN WHO ARE INFERTILE BECAUSE OF INSUFFICIENT GONADOTROPINS. ...OCCURRENCE OF OVULATION IN 75% OF PT TREATED WITH DRUGS. /GONADOTROPINS/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1388
WHILE OVULATION WAS OCCASIONALLY SEEN DURING ADMIN OF MENOTROPINS BEFORE HUMAN CHORIONIC GONADOTROPIN...GIVEN, IT USUALLY TOOK PLACE ABOUT 18 HR AFTER ADMIN OF LATTER HORMONE. PREGNANCY RESULTED IN APPROX 25% OF PT... 20% OF PREGNANCIES RESULTED IN MULTIPLE BIRTHS...
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1388
GROWTH & DEVELOPMENT OF CHILDREN BORN OF MOTHERS RECEIVING GONADOTROPIN TREATMENT HAVE BEEN NORMAL... /GONADOTROPINS/
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1388
For more Therapeutic Uses (Complete) data for MENOTROPINS (6 total), please visit the HSDB record page.
...ABORTION RATE...25% & FETAL ABNORMALITIES...IN 2%.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1388
For the treatment of female infertility
FDA Label
Treatment of female infertility
Used to treat female infertility, Menotropins stimulates late follicular maturation and resumption of oocyte meiosis, and initiates rupture of the pre-ovulatory ovarian follicle. Menotropins bind to the LH/hCG/FSH receptor of the granulosa and theca cells of the ovary to effect these changes in the absence of an endogenous LH surge.
Fertility Agents, Female
Compounds which increase the capacity to conceive in females. (See all compounds classified as Fertility Agents, Female.)
G - Genito urinary system and sex hormones
G03 - Sex hormones and modulators of the genital system
G03G - Gonadotropins and other ovulation stimulants
G03GA - Gonadotropins
G03GA02 - Human menopausal gonadotrophin
LENGTH OF SURVIVAL OF INJECTED & PRESUMABLY OF ENDOGENOUSLY SECRETED HORMONES IS DETERMINED LARGELY BY RATE OF DEGRADATION IN BODY, BECAUSE LITTLE IS EXCRETED IN URINE...
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1387
STUDIES ON RATE OF DISAPPEARANCE OF ENDOGENOUS HUMAN...FSH...INDICATE REMOVAL FROM PLASMA WITH @ LEAST 2 DISTINCT HALF-TIMES. SHORTER HALF-LIVES...APPROX 4 HR...WHILE LONGER HALF-LIVES APPEAR TO BE 70 /HR/...ONLY 5% OF SECRETED FSH IS FOUND IN URINE IN ACTIVE FORM...
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1387
MEASUREMENTS OF GONADOTROPINS IN PLASMA THROUGHOUT MENSTRUAL CYCLE SHOW THAT FSH IS ELEVATED DURING FOLLICULAR PHASE & SLOWLY FALLS BEFORE IT RISES AGAIN AT MIDCYCLE; IT IS LOWEST DURING LUTEAL PHASE. .../AT MIDCYCLE/ FSH IS HIGHEST.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1386
Being a combination drug, Menotropins bind to the follicle stimulating hormone receptor (FSH), which results in ovulation in the absence of sufficient endogenous luteinizing hormone (LH). It also binds the LH receptor, thereby stimulating proper hormone release. The drug contains both FSH and LH, therefore, it induces ovarian follicular growth and development as well as gonadal steroid production in women who do not have ovarian failure. FSH is the primary driver of follicular recruitment and growth in early folliculogenesis, while LH is important for ovarian steroidogenesis and is involved in the physiological events leading to development of a competent pre-ovulatory follicle.
...LH & FSH BIND WITH APPARENT SPECIFICITY TO VARIOUS PARTICULATE FRACTIONS DERIVED FROM TESTIS & OVARY. ...BOTH GONADOTROPINS ARE KNOWN TO STIMULATE CYCLIC AMP SYNTHESIS IN APPROPRIATE GONADAL PREPN. CYCLIC AMP THEN STIMULATES SEX STEROID BIOSYNTHESIS BY MECHANISMS APPARENTLY ANALOGOUS TO THOSE OPERATIVE IN ADRENAL CORTEX.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1387
.../FSH/ CONSISTS OF NONIDENTICAL, NON-COVALENTLY LINKED SUBUNITS... WHILE THE ALPHA SUBUNIT OF FSH IS SIGNIFICANTLY DIFFERENT FROM THAT OF LH OR TSH...THERE IS EVIDENCE THAT FSH ALPHA SUBUNIT CAN COMBINE WITH BETA SUBUNIT OF CHORIONIC GONADOTROPIN WITH RESTORATION OF CHORIONIC GONADODTROPIN ACTIVITY...
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1385
DURING FOLLICULAR PHASE OF OVARIAN CYCLE SUCCESSIVE GROUPS OF SMALL FOLLICLES START TO GROW, & BY TIME OVULATION IS IMMINENT FOLLICLES IN ALL STAGES OF DEVELOPMENT ARE FOUND. THIS OVARIAN RESPONSE REPRESENTS PREDOMINANT ACTION OF FSH, IT IS DURING THIS PHASE THAT ESTROGEN IS MAIN OVARIAN SECRETORY PRODUCT...
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1386
FSH IS PRIMARILY A GAMETOGENIC HORMONE IN MALES; IT IS RESPONSIBLE FOR ANATOMICAL INTEGRITY OF SEMINIFEROUS TUBULES & ONLY UNDER ITS INFLUENCE ARE COMPLEX STAGES OF GAMETOGENESIS CARRIED THROUGH TO PRODUCTION OF SPERMATOZOA.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 1386
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]NDC API
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
Drugs in Development
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDF Dossiers
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]FDA Orange Book
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Europe
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Canada
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
Global Sales Information
Market Place
ABOUT THIS PAGE
A Menotropins manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Menotropins, including repackagers and relabelers. The FDA regulates Menotropins manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Menotropins API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Menotropins supplier is an individual or a company that provides Menotropins active pharmaceutical ingredient (API) or Menotropins finished formulations upon request. The Menotropins suppliers may include Menotropins API manufacturers, exporters, distributors and traders.
click here to find a list of Menotropins suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Menotropins DMF (Drug Master File) is a document detailing the whole manufacturing process of Menotropins active pharmaceutical ingredient (API) in detail. Different forms of Menotropins DMFs exist exist since differing nations have different regulations, such as Menotropins USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Menotropins DMF submitted to regulatory agencies in the US is known as a USDMF. Menotropins USDMF includes data on Menotropins's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Menotropins USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Menotropins suppliers with USDMF on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Menotropins as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Menotropins API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Menotropins as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Menotropins and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Menotropins NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Menotropins suppliers with NDC on PharmaCompass.
Menotropins Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Menotropins GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Menotropins GMP manufacturer or Menotropins GMP API supplier for your needs.
A Menotropins CoA (Certificate of Analysis) is a formal document that attests to Menotropins's compliance with Menotropins specifications and serves as a tool for batch-level quality control.
Menotropins CoA mostly includes findings from lab analyses of a specific batch. For each Menotropins CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Menotropins may be tested according to a variety of international standards, such as European Pharmacopoeia (Menotropins EP), Menotropins JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Menotropins USP).
LOOKING FOR A SUPPLIER?
